100140-99-6Relevant academic research and scientific papers
Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold
Cappelli, Andrea,Bini, Giulia,Valenti, Salvatore,Giuliani, Germano,Paolino, Marco,Anzini, Maurizio,Vomero, Salvatore,Giorgi, Gianluca,Giordani, Antonio,Stasi, Luigi Piero,Makovec, Francesco,Ghelardini, Carla,Di Cesare Mannelli, Lorenzo,Concas, Alessandra,Porcu, Patrizia,Biggio, Giovanni
supporting information; experimental part, p. 7165 - 7175 (2011/12/04)
As a further development of our large program focused on the medicinal chemistry of translocator protein [TSPO (18 kDa)] ligands, a new class of compounds related to alpidem has been designed using SSR180575, emapunil, and previously published pyrrolo[3,4-b]quinoline derivatives 9 as templates. The designed compounds were synthesized by alkylation of the easily accessible 4-methyl-2-phenyl-1H-pyrazolo[3,4-b]quinolin-3(2H)-one derivatives 13-15 with the required bromoacetamides. Along with the expected 2-(4-methyl-3-oxo-2- phenyl-2,3-dihydro-1H-pyrazolo[3,4-b]quinolin-1-yl)acetamide derivatives 10, 2-(4-methyl-3-oxo-2-phenyl-2H-pyrazolo[3,4-b]quinolin-9(3H)-yl)acetamide isomers 11 were isolated and characterized. The high TSPO affinity shown by new pyrazolo[3,4-b]quinoline derivatives 10 and especially 11 leads the way to further expand the chemical diversity in TSPO ligands and provides new templates and structure-affinity relationship data potentially useful in the design of new anxiolytic and neuroprotective agents.
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5- dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity
Elliott, Richard L.,Cameron, Kimberly O.,Chin, Janice E.,Bartlett, Jeremy A.,Beretta, Elena E.,Chen, Yue,Jardine, Paul Da Silva,Dubins, Jeffrey S.,Gillaspy, Melissa L.,Hargrove, Diane M.,Kalgutkar, Amit S.,Laflamme, Janet A.,Lame, Mary E.,Martin, Kelly A.,Maurer, Tristan S.,Nardone, Nancy A.,Oliver, Robert M.,Scott, Dennis O.,Sun, Dexue,Swick, Andrew G.,Trebino, Catherine E.,Zhang, Yingxin
supporting information; experimental part, p. 6797 - 6801 (2011/01/04)
We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts
Tetraazabenzo[e]azulene derivatives and analogs thereof
-
Page/Page column 40, (2010/02/14)
This invention relates to CCK-A agonists of Formula (I) wherein R1-R4, A, B, X, D, E and G are as defined in the specificiation, as well as, among other things, pharmaceutical compositions containing the compounds and methods of use of the compounds and compositions. The compounds are useful in treating obesity.
Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger"
Aquino, Christopher J.,Armour, Duncan R.,Berman, Judd M.,Birkemo, Larry S.,Carr, Robin A. E.,Croom, Dallas K.,Dezube, Milana,Dougherty Jr., Robert W.,Ervin, Gregory N.,Grizzle, Mary K.,Head, Julie E.,Hirst, Gavin C.,James, Michael K.,Johnson, Michael F.,Miller, Laurence J.,Queen, Kennedy L.,Rimele, Thomas J.,Smith, David N.,Sugg, Elizabeth E.
, p. 562 - 569 (2007/10/03)
Directed screening of compounds selected from the Glaxo registry file for contractile activity on the isolated guinea pig gallbladder (GPGB) identified a series of 1,5-benzodiazepines with peripheral cholecystokinin (CCK) receptor agonist activity. Agonis
